Literature DB >> 31960950

Epidemiology and management of uterine fibroids.

Emma Giuliani1, Sawsan As-Sanie2, Erica E Marsh1.   

Abstract

Uterine leiomyomas are one of the most common and yet understudied diseases in women. These tumors, commonly known as fibroids, affect women mainly during their reproductive years and are diagnosed in up to 70% of white women and more than 80% of women of African ancestry during their lifetime. This disease has a profound impact on health care delivery and costs worldwide. Though most women with fibroids are asymptomatic, approximately 30% of them will present with severe symptoms which can include abnormal uterine bleeding, anemia, pelvic pain and pressure, back pain, urinary frequency, constipation, or infertility, and will require intervention. Furthermore, fibroids have been associated with poor obstetrical outcomes. The current options for symptomatic fibroid treatment include expectant, medical, and surgical management, and interventional radiology procedures. This article reviews the recent progress and available management strategies for uterine fibroids and highlights areas where further research is needed to find new therapeutic targets and better personalize treatments.
© 2020 International Federation of Gynecology and Obstetrics.

Entities:  

Keywords:  Abnormal uterine bleeding; Leiomyomas; Uterine fibroids

Mesh:

Year:  2020        PMID: 31960950     DOI: 10.1002/ijgo.13102

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  45 in total

1.  [Robot-assisted laparoscopic total hysterectomy in a patient with giant uterine fibroids and complex pelvic adhesions: a case report].

Authors:  M Chen; N Wang; Y Ye; M Wang; Z Li; Y Meng; M Ye
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-02-20

Review 2.  Current approaches to overcome the side effects of GnRH analogs in the treatment of patients with uterine fibroids.

Authors:  Mohamed Ali; Mohamed Raslan; Michał Ciebiera; Kornelia Zaręba; Ayman Al-Hendy
Journal:  Expert Opin Drug Saf       Date:  2021-10-20       Impact factor: 4.250

3.  Rare Case of Osseus Metaplasia in a Detached Remnant Leiomyoma Following Hysteroscopic Myomectomy.

Authors:  Maha Al Jumaily; Emad Mikhail
Journal:  Cureus       Date:  2022-04-15

4.  Non-hormonal mediators of uterine fibroid growth.

Authors:  Esra Cetin; Ayman Al-Hendy; Michał Ciebiera
Journal:  Curr Opin Obstet Gynecol       Date:  2020-10       Impact factor: 1.927

Review 5.  The role of endocrine-disrupting chemicals in uterine fibroid pathogenesis.

Authors:  Maria Victoria Bariani; Roshni Rangaswamy; Hiba Siblini; Qiwei Yang; Ayman Al-Hendy; Ami R Zota
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2020-12       Impact factor: 3.243

Review 6.  Vitamin D: Mechanism of Action and Biological Effects in Uterine Fibroids.

Authors:  Daniele Vergara; William H Catherino; Giuseppe Trojano; Andrea Tinelli
Journal:  Nutrients       Date:  2021-02-11       Impact factor: 5.717

7.  Robotic single-site versus multi-port myomectomy: a case-control study.

Authors:  So Hyun Ahn; Joo Hyun Park; Hye Rim Kim; SiHyun Cho; Myeongjee Lee; Seok Kyo Seo; Young Sik Choi; Byung Seok Lee
Journal:  BMC Surg       Date:  2021-05-27       Impact factor: 2.102

8.  MicroRNA-139-5p Regulates Fibrotic Potentials via Modulation of Collagen Type 1 and Phosphorylated p38 MAPK in Uterine Leiomyoma.

Authors:  So Hyun Ahn; Heeyon Kim; Inha Lee; Jae Hoon Lee; SiHyun Cho; Young Sik Choi
Journal:  Yonsei Med J       Date:  2021-08       Impact factor: 2.759

9.  Red degeneration of a large leiomyoma in a non-pregnant woman in pursuit of 17 pregnancies: a case report.

Authors:  Dema Adwan; Sami Jomaa
Journal:  J Surg Case Rep       Date:  2021-07-15

10.  Diagnostic Value of Preoperative CA125, LDH and HE4 for Leiomyosarcoma of the Female Reproductive System.

Authors:  Fenfen Zhang; Yao Liu; Quan Quan; Yu Meng; Xiaoling Mu
Journal:  Cancer Manag Res       Date:  2021-06-14       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.